{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:07:43Z","timestamp":1789542463467,"version":"build-2803163510"},"reference-count":180,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disord Clin Pract"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In patients with fluctuating Parkinson's disease (PD), treatment decisions predominantly focus on motor complications, whereas neuropsychiatric symptoms are often regarded as static. Neuropsychiatric fluctuations (NPF), however, are frequent, can rival or exceed motor symptoms in their impact on quality of life, and may predispose patients to persistent neuropsychiatric complications if left unrecognized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To propose a structured approach to the definition, mechanistic underpinnings, assessment, and management of NPF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Narrative review of clinical and mechanistic studies on NPF in patients with fluctuating PD, complemented by the authors\u2019 clinical and research experience in the recognition and management of these phenomena. Findings were synthesized to provide a structured overview of their clinical characteristics, underlying mechanisms, assessment, and management, and to inform the proposed framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>NPF are characterized by intradiurnal changes in mood, motivation, anxiety, and cognition that closely track the short\u2010term pharmacodynamics of dopaminergic therapy, reflecting transitions between relative dopaminergic deficiency during OFF periods and excessive dopaminergic stimulation during peak dose states. Converging clinical and mechanistic evidence supports dynamic fluctuations in dopaminergic tone within limbic and associative circuits as a key driver of NPF, whereas other neurotransmitter systems may also modulate their clinical expression. Recognition of NPF remains difficult because, unlike motor complications, they are less amenable to objective observation and quantification, patient self\u2010report is often limited by impaired insight, and commonly used PD rating scales fail to capture these phenomena. Consequently, effective management requires early identification and therapeutic strategies aimed at stabilizing dopaminergic tone within mesolimbic and mesocortical circuits. Timely detection and proactive treatment adjustments may help limit the progression and severity of neuropsychiatric complications over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>To move beyond a motor\u2010centric paradigm, the field requires consensus definitions, improved understanding of underlying mechanisms, validated assessment instruments, and clinical trials that prioritize NPF as primary outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mdc3.70771","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:58:13Z","timestamp":1789541893000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding Neuropsychiatric Fluctuations in Parkinson's Disease: From Mechanisms to Management"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2570-6435","authenticated-orcid":false,"given":"Mario","family":"Sousa","sequence":"first","affiliation":[{"name":"Department of Neurology Inselspital, University Hospital Bern, University of Bern  Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Amstutz","sequence":"additional","affiliation":[{"name":"Department of Neurology Inselspital, University Hospital Bern, University of Bern  Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Natera\u2010Villalba","sequence":"additional","affiliation":[{"name":"Movement Disorders Unit, Neurology Department Cl\u00ednica Universidad de Navarra  Madrid\u2010Pamplona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Krack","sequence":"additional","affiliation":[{"name":"Department of Neurology Inselspital, University Hospital Bern, University of Bern  Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0305-013X","authenticated-orcid":false,"given":"Ra\u00fal","family":"Mart\u00ednez\u2010Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Movement Disorders Unit, Neurology Department Hospital de la Santa Creu i Sant Pau  Barcelona Spain"},{"name":"Institut de Recerca Sant Pau (IR SANT PAU)  Barcelona Spain"},{"name":"HM CINAC University Hospital HM Puerta del Sur, HM Hospitales  Madrid Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria HM Hospitales  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.parkreldis.2015.03.024","article-title":"Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease","volume":"21","author":"Martinez\u2010Martin P","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"e_1_2_14_3_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1474-4422(14)70287-X","article-title":"Prediagnostic presentations of Parkinson's disease in primary care: a case\u2010control study","volume":"14","author":"Schrag A","year":"2015","journal-title":"Lancet Neurol"},{"key":"e_1_2_14_4_1","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/mds.26731","article-title":"The hidden sister of motor fluctuations in Parkinson's disease: a review on nonmotor fluctuations","volume":"31","author":"Mart\u00ednez\u2010Fern\u00e1ndez R","year":"2016","journal-title":"Mov Disord"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.59.3.408"},{"key":"e_1_2_14_6_1","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/WNL.0b013e318285c0ed","article-title":"Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications","volume":"80","author":"Storch A","year":"2013","journal-title":"Neurology"},{"key":"e_1_2_14_7_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1149615","article-title":"Impact of non\u2010motor fluctuations on QOL in patients with Parkinson's disease","volume":"14","author":"Kakimoto A","year":"2023","journal-title":"Front Neurol"},{"key":"e_1_2_14_8_1","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00702-017-1757-0","article-title":"Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues","volume":"124","author":"Classen J","year":"2017","journal-title":"J Neural Transm"},{"key":"e_1_2_14_9_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14802\/jmd.24227","article-title":"Non\u2010motor fluctuations in Parkinson's disease: underdiagnosed yet important","volume":"18","author":"Boura I","year":"2025","journal-title":"J Mov Disord"},{"key":"e_1_2_14_10_1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2018.04.020","article-title":"Emergence of non\u2010motor fluctuations with reference to motor fluctuations in Parkinson's disease","volume":"54","author":"Kim A","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"e_1_2_14_11_1","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1007\/s10072-021-05833-8","article-title":"Do neuropsychiatric fluctuations temporally match motor fluctuations in Parkinson's disease?","volume":"43","author":"Prete E","year":"2022","journal-title":"Neurol Sci"},{"key":"e_1_2_14_12_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1176\/jnp.13.1.35","article-title":"Relationship between mood and motor fluctuations in Parkinson's disease","volume":"13","author":"Richard IH","year":"2001","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"e_1_2_14_13_1","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1093\/brain\/awad162","article-title":"Impulse control disorder in Parkinson's disease is associated with abnormal frontal value signalling","volume":"146","author":"Tichelaar JG","year":"2023","journal-title":"Brain"},{"key":"e_1_2_14_14_1","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/ana.20822","article-title":"Compulsive drug use linked to sensitized ventral striatal dopamine transmission","volume":"59","author":"Evans AH","year":"2006","journal-title":"Ann Neurol"},{"key":"e_1_2_14_15_1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ana.26164","article-title":"Changing gears \u2013 DBS for dopaminergic desensitization in Parkinson's disease?","volume":"90","author":"Weiss D","year":"2021","journal-title":"Ann Neurol"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq032"},{"key":"e_1_2_14_17_1","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/brain\/awt067","article-title":"Parkinsonian apathy responds to dopaminergic stimulation of D2\/D3 receptors with piribedil","volume":"136","author":"Thobois S","year":"2013","journal-title":"Brain"},{"key":"e_1_2_14_18_1","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1002\/mds.28722","article-title":"Serotonergic and dopaminergic lesions underlying parkinsonian neuropsychiatric signs","volume":"36","author":"Maillet A","year":"2021","journal-title":"Mov Disord"},{"key":"e_1_2_14_19_1","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/brain\/awaf087","article-title":"Serotonergic dysfunction in patients with impulse control disorders in Parkinson's disease","volume":"148","author":"Prange S","year":"2025","journal-title":"Brain"},{"key":"e_1_2_14_20_1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41531-026-01294-y","article-title":"Serotonergic cortico\u2010limbic and executive network dysfunction in Parkinson's disease impulse control disorders: a PET\u2010fMRI study","volume":"12","author":"Terenzi D","year":"2026","journal-title":"NPJ Park Dis"},{"key":"e_1_2_14_21_1","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/brain\/awad338","article-title":"Noradrenergic alterations in Parkinson's disease: a combined 11C\u2010yohimbine PET\/neuromelanin MRI study","volume":"147","author":"Laurencin C","year":"2024","journal-title":"Brain"},{"key":"e_1_2_14_22_1","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.neuroimage.2011.03.012","article-title":"Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F\u2010dopa PET study","volume":"56","author":"Pavese N","year":"2011","journal-title":"Neuroimage"},{"key":"e_1_2_14_23_1","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mdc3.13520","article-title":"Characterization of non\u2010motor fluctuations using the Movement Disorder Society Non\u2010Motor rating scale","volume":"9","author":"Wamelen DJ","year":"2022","journal-title":"Mov Disord Clin Pract"},{"key":"e_1_2_14_24_1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1474-4422(21)00330-6","article-title":"The neuropsychiatry of Parkinson's disease: advances and challenges","volume":"21","author":"Weintraub D","year":"2022","journal-title":"Lancet Neurol"},{"key":"e_1_2_14_25_1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3233\/JPD-181462","article-title":"Shame in Parkinson'S disease: a review","volume":"9","author":"Angulo J","year":"2019","journal-title":"J Parkinsons Dis"},{"key":"e_1_2_14_26_1","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1212\/WNL.45.9.1757","article-title":"Dose\u2010response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double\u2010blind, placebo\u2010controlled study","volume":"45","author":"Maricle RA","year":"1995","journal-title":"Neurology"},{"key":"e_1_2_14_27_1","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.neurol.2009.06.003","article-title":"\u00c9valuation des troubles comportementaux hyper\u2010 et hypodopaminergiques dans la maladie de Parkinson","volume":"165","author":"Ardouin C","year":"2009","journal-title":"Rev Neurol (Paris)"},{"key":"e_1_2_14_28_1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.neurol.2018.07.005","article-title":"Hyperdopaminergic behavioral spectrum in Parkinson's disease: a review","volume":"174","author":"B\u00e9reau M","year":"2018","journal-title":"Rev Neurol (Paris)"},{"key":"e_1_2_14_29_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.neurol.2024.11.004","article-title":"Psychiatric and cognitive symptoms of Parkinson's disease: a life's tale","volume":"181","author":"Amstutz D","year":"2025","journal-title":"Rev Neurol (Paris)"},{"key":"e_1_2_14_30_1","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1093\/brain\/awad064","article-title":"Impaired dopamine release in Parkinson's disease","volume":"146","author":"Cramb KML","year":"2023","journal-title":"Brain"},{"key":"e_1_2_14_31_1","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","article-title":"Levodopa\u2010induced dyskinesias in patients with Parkinson's disease: filling the bench\u2010to\u2010bedside gap","volume":"9","author":"Calabresi P","year":"2010","journal-title":"Lancet Neurol"},{"key":"e_1_2_14_32_1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3233\/JPD-150535","article-title":"Apathy and impulse control disorders: yin & Yang of dopamine dependent behaviors","volume":"5","author":"Sierra M","year":"2015","journal-title":"J Parkinsons Dis"},{"key":"e_1_2_14_33_1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(76)91416-1","article-title":"\u2018On\u2010off\u2019 effects in patients with Parkinson's disease on chronic levodopa therapy","volume":"1","author":"Marsden CD","year":"1976","journal-title":"Lancet (London, England)"},{"key":"e_1_2_14_34_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/jnnp.52.Suppl.29","article-title":"The on\u2010off phenomenon","volume":"52","author":"Lees AJ","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_14_35_1","unstructured":"O'SullivanSS EvansAH LeesAJ.Dopamine Dysregulation Syndrome;2009."},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70590"},{"key":"e_1_2_14_37_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000214934","article-title":"Cognitive fluctuations, neuropsychiatric burden, and quality of life in moderate\u2010advanced dementia with Lewy bodies: the role of dysautonomia","volume":"106","author":"Mahajan A","year":"2026","journal-title":"Neurology"},{"key":"e_1_2_14_38_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2025-001497","article-title":"Hallucinations and cognitive impairment are associated with blood pressure fluctuations in Parkinson's disease","volume":"8","author":"Nomoto S","year":"2026","journal-title":"BMJ Neurol Open"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2026.102036"},{"key":"e_1_2_14_40_1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.parkreldis.2016.04.001","article-title":"Gender and non motor fluctuations in Parkinson's disease: a prospective study","volume":"27","author":"Picillo M","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"e_1_2_14_41_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/mds.870010112","article-title":"Menstrual\u2010related fluctuations in Parkinson's disease","volume":"1","author":"Quinn NP","year":"1986","journal-title":"Mov Disord"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-026-01323-w"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.65"},{"key":"e_1_2_14_44_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/mdc3.12607","article-title":"The neuropsychiatric fluctuations scale for Parkinson's disease: a pilot study","volume":"5","author":"Schmitt E","year":"2018","journal-title":"Mov Disord Clin Pract"},{"key":"e_1_2_14_45_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2025.107954","article-title":"Neuropsychiatric fluctuations in Parkinson's disease: a French multicenter study of the NFS psychometric properties","volume":"138","author":"Schmitt E","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"key":"e_1_2_14_46_1","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/jnnp-2023-332551","article-title":"ON\/OFF non\u2010motor evaluation: a new way to evaluate non\u2010motor fluctuations in Parkinson's disease","volume":"95","author":"Faggianelli F","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_14_47_1","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/mds.21944","article-title":"Validation of the \u201cQUICK\u201d questionnaire\u2014a tool for diagnosis of \u201cwearing\u2010off\u201d in patients with Parkinson's disease","volume":"23","author":"Martinez\u2010Martin P","year":"2008","journal-title":"Mov Disord"},{"key":"e_1_2_14_48_1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.parkreldis.2007.07.013","article-title":"The sensitivity and specificity of the 9\u2010item wearing\u2010off questionnaire","volume":"14","author":"Stacy MA","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"key":"e_1_2_14_49_1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/mds.26223","article-title":"International validation of a behavioral scale in Parkinson's disease without dementia","volume":"30","author":"Rieu I","year":"2015","journal-title":"Mov Disord"},{"key":"e_1_2_14_50_1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/mds.27862","article-title":"The Movement Disorder Society nonmotor rating scale: initial validation study","volume":"35","author":"Chaudhuri KR","year":"2020","journal-title":"Mov Disord"},{"key":"e_1_2_14_51_1","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/mds.28507","article-title":"Non\u2010motor fluctuations in Parkinson's disease: validation of the non\u2010motor fluctuation assessment questionnaire","volume":"36","author":"Kleiner G","year":"2021","journal-title":"Mov Disord"},{"key":"e_1_2_14_52_1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.neurol.2021.06.013","article-title":"Validation of a non\u2010motor fluctuations questionnaire in Parkinson's disease","volume":"178","author":"Faggianelli F","year":"2022","journal-title":"Rev Neurol (Paris)"},{"key":"e_1_2_14_53_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-025-00937-w","article-title":"Improvement of apathy in early Parkinson's disease","volume":"11","author":"Castrioto A","year":"2025","journal-title":"NPJ Park Dis"},{"key":"e_1_2_14_54_1","first-page":"167","article-title":"Overview of the extranigral aspects of Parkinson disease","volume":"66","author":"Lim S\u2010Y","year":"2009","journal-title":"Arch Neurol"},{"key":"e_1_2_14_55_1","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/brain\/awh102","article-title":"Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model","volume":"127","author":"Fuente\u2010Fern\u00e1ndez R","year":"2004","journal-title":"Brain"},{"key":"e_1_2_14_56_1","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3233\/JPD-223223","article-title":"Apathy reflects extra\u2010striatal dopaminergic degeneration in de novo Parkinson's disease","volume":"12","author":"Sampedro F","year":"2022","journal-title":"J Parkinsons Dis"},{"key":"e_1_2_14_57_1","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1523\/JNEUROSCI.3082-17.2018","article-title":"Nigrostriatal and mesolimbic D2\/3 receptor expression in Parkinson's disease patients with compulsive reward\u2010driven behaviors","volume":"38","author":"Stark AJ","year":"2018","journal-title":"J Neurosci"},{"key":"e_1_2_14_58_1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neubiorev.2013.11.001","article-title":"Depression and impulse control disorders in Parkinson's disease: two sides of the same coin?","volume":"38","author":"Vriend C","year":"2014","journal-title":"Neurosci Biobehav Rev"},{"key":"e_1_2_14_59_1","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/mds.26587","article-title":"Emotional manifestations of PD: neurobiological basis","volume":"31","author":"Castrioto A","year":"2016","journal-title":"Mov Disord"},{"key":"e_1_2_14_60_1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/jnnp-2012-302444","article-title":"Psychostimulant effect of levodopa: reversing sensitisation is possible","volume":"84","author":"Castrioto A","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_14_61_1","unstructured":"WeintraubD.Impulse Control Disorders in Parkinson's Disease; Treat. PSYCHIATRY."},{"key":"e_1_2_14_62_1","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bph.12988","article-title":"Rotigotine is a potent agonist at dopamine D\n                  1 receptors as well as at dopamine D\n                  2 and D\n                  3 receptors","volume":"172","author":"Wood M","year":"2015","journal-title":"Br J Pharmacol"},{"key":"e_1_2_14_63_1","unstructured":"BorgemeesterRWK LeesAJ vanLaarT.Parkinson's disease visual hallucinations and apomorphine: A review of the available evidence."},{"key":"e_1_2_14_64_1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/mds.29700","article-title":"Management of Impulse Control and Related Disorders in Parkinson's disease: an expert consensus","volume":"39","author":"Debove I","year":"2024","journal-title":"Mov Disord"},{"key":"e_1_2_14_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70240"},{"key":"e_1_2_14_66_1","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mds.29410","article-title":"Levodopa dose equivalency in Parkinson's disease: updated systematic review and proposals","volume":"38","author":"Jost ST","year":"2023","journal-title":"Mov Disord"},{"key":"e_1_2_14_67_1","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1111\/ejn.14177","article-title":"Pharmacological insights into impulsive\u2010compulsive spectrum disorders associated with dopaminergic therapy","volume":"50","author":"Napier TC","year":"2019","journal-title":"Eur J Neurosci"},{"key":"e_1_2_14_68_1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/syn.21805","article-title":"Parkinson's disease treatment may cause impulse\u2010control disorder via dopamine D3 receptors: impulse\u2010control disorder and D3 receptors","volume":"69","author":"Seeman P","year":"2015","journal-title":"Synapse"},{"key":"e_1_2_14_69_1","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/brain\/awp054","article-title":"Increased striatal dopamine release in parkinsonian patients with pathological gambling: a [11C] raclopride PET study","volume":"132","author":"Steeves TDL","year":"2009","journal-title":"Brain"},{"key":"e_1_2_14_70_1","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S1474-4422(09)70287-X","article-title":"Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders","volume":"8","author":"Voon V","year":"2009","journal-title":"Lancet Neurol"},{"key":"e_1_2_14_71_1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jns.2011.07.012","article-title":"Dopaminergic dysregulation syndrome in Parkinson's disease","volume":"310","author":"Katzenschlager R","year":"2011","journal-title":"J Neurol Sci"},{"key":"e_1_2_14_72_1","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.3390\/ijms26083866","article-title":"Behavioral effects of stimulated dopamine release and D2\u2010like receptor displacement in Parkinson's patients with impulse\u2010control disorder","volume":"26","author":"Aumann MA","year":"2025","journal-title":"Int J Mol Sci"},{"key":"e_1_2_14_73_1","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.neurol.2010.07.006","article-title":"Maladie de Parkinson\u2009: de la physiopathologie des troubles psychiques \u00e0 la ma\u00eetrise du traitement dopaminergique","volume":"166","author":"Thobois S","year":"2010","journal-title":"Rev Neurol (Paris)"},{"key":"e_1_2_14_74_1","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1002\/mds.22792","article-title":"Role of serotonin neurons in the induction of levodopa\u2010 and graft\u2010induced dyskinesias in Parkinson's disease","volume":"25","author":"Carta M","year":"2010","journal-title":"Mov Disord"},{"key":"e_1_2_14_75_1","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1007\/s00415-022-10963-w","article-title":"Levodopa\u2010induced dyskinesia: a historical review of Parkinson's disease, dopamine, and modern advancements in research and treatment","volume":"269","author":"Hansen CA","year":"2022","journal-title":"J Neurol"},{"key":"e_1_2_14_76_1","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.26067","article-title":"EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease","volume":"30","author":"Martinez\u2010Martin P","year":"2015","journal-title":"Mov Disord"},{"key":"e_1_2_14_77_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1242484","article-title":"Fluctuations in Parkinson's disease and personalized medicine: bridging the gap with the neuropsychiatric fluctuation scale","volume":"14","author":"Schmitt E","year":"2023","journal-title":"Front Neurol"},{"key":"e_1_2_14_78_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2023-000524","article-title":"Subthalamic stimulation has acute psychotropic effects and improves neuropsychiatric fluctuations in Parkinson's disease","volume":"6","author":"Magalh\u00e3es AD","year":"2024","journal-title":"BMJ Neurol Open"},{"key":"e_1_2_14_79_1","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1007\/s00415-020-09810-7","article-title":"Levodopa challenge test: indications, protocol, and guide","volume":"268","author":"Saranza G","year":"2021","journal-title":"J Neurol"},{"key":"e_1_2_14_80_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","article-title":"A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia","volume":"23","author":"Hauser RA","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_14_81_1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41746-022-00568-y","article-title":"Co\u2010evolution of machine learning and digital technologies to improve monitoring of Parkinson's disease motor symptoms","volume":"5","author":"Chandrabhatla AS","year":"2022","journal-title":"NPJ Digit Med"},{"key":"e_1_2_14_82_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-023-00585-y","article-title":"Overview on wearable sensors for the management of Parkinson's disease","volume":"9","author":"Moreau C","year":"2023","journal-title":"NPJ Park Dis"},{"key":"e_1_2_14_83_1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41746-024-01217-2","article-title":"Digital biomarkers for precision diagnosis and monitoring in Parkinson's disease","volume":"7","author":"Sun Y","year":"2024","journal-title":"NPJ Digit Med"},{"key":"e_1_2_14_84_1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41746-024-01144-2","article-title":"Digital biomarkers for non\u2010motor symptoms in Parkinson's disease: the state of the art","volume":"7","author":"Janssen Daalen JM","year":"2024","journal-title":"NPJ Digit Med"},{"key":"e_1_2_14_85_1","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6579\/adf6fe","article-title":"Prescreening depression using wearable electrocardiogram and photoplethysmogram data from a psycholinguistic experiment","volume":"46","author":"Karimi S","year":"2025","journal-title":"Physiol Meas"},{"key":"e_1_2_14_86_1","doi-asserted-by":"crossref","first-page":"12601","DOI":"10.3390\/ijms241612601","article-title":"Clinical and non\u2010clinical cardiovascular disease associated pathologies in Parkinson's disease","volume":"24","author":"Lee B","year":"2023","journal-title":"Int J Mol Sci"},{"key":"e_1_2_14_87_1","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00702-022-02528-y","article-title":"Wearable sensor device\u2010based detection of decreased heart rate variability in Parkinson's disease","volume":"129","author":"Suzuki M","year":"2022","journal-title":"J Neural Transm"},{"key":"e_1_2_14_88_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081233","article-title":"Objective measurement of daytime napping, cognitive dysfunction and subjective sleepiness in Parkinson's disease","volume":"8","author":"Bolitho SJ","year":"2013","journal-title":"PLoS One"},{"key":"e_1_2_14_89_1","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.3390\/s20185171","article-title":"Shedding light on nocturnal movements in Parkinson's disease: evidence from wearable technologies","volume":"20","author":"Zampogna A","year":"2020","journal-title":"Sensors"},{"key":"e_1_2_14_90_1","doi-asserted-by":"crossref","first-page":"eabd7865","DOI":"10.1126\/scitranslmed.abd7865","article-title":"Smartwatch inertial sensors continuously monitor real\u2010world motor fluctuations in Parkinson's disease","volume":"13","author":"Powers R","year":"2021","journal-title":"Sci Transl Med"},{"key":"e_1_2_14_91_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0275747","article-title":"Digital phenotyping by wearable\u2010driven artificial intelligence in older adults and people with Parkinson's disease: protocol of the mixed method, cyclic ActiveAgeing study","volume":"17","author":"Torrado JC","year":"2022","journal-title":"PLoS One"},{"key":"e_1_2_14_92_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41598-023-48209-y","article-title":"Home\u2010based monitoring of persons with advanced Parkinson's disease using smartwatch\u2010smartphone technology","volume":"14","author":"Fay\u2010Karmon T","year":"2024","journal-title":"Sci Rep"},{"key":"e_1_2_14_93_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-025-00876-6","article-title":"VisionMD: an open\u2010source tool for video\u2010based analysis of motor function in movement disorders","volume":"11","author":"Acevedo G","year":"2025","journal-title":"NPJ Park Dis"},{"key":"e_1_2_14_94_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-017-0038-9","article-title":"The use of accelerometry as a tool to measure disturbed nocturnal sleep in Parkinson's disease","volume":"4","author":"McGregor S","year":"2018","journal-title":"NPJ Park Dis"},{"key":"e_1_2_14_95_1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3389\/fneur.2019.00356","article-title":"Validation of a device for the ambulatory monitoring of sleep patterns: a pilot study on Parkinson's disease","volume":"10","author":"Madrid\u2010Navarro CJ","year":"2019","journal-title":"Front Neurol"},{"key":"e_1_2_14_96_1","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/mds.28006","article-title":"Tossing and turning in bed: nocturnal movements in Parkinson's disease","volume":"35","author":"Mirelman A","year":"2020","journal-title":"Mov Disord"},{"key":"e_1_2_14_97_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12883-025-04030-w","article-title":"Changes in sensor recorded activity patterns and neuropsychiatric symptoms after deep brain stimulation for Parkinson's disease: 5 case reports","volume":"25","author":"Bruhin LC","year":"2025","journal-title":"BMC Neurol"},{"key":"e_1_2_14_98_1","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/mds.29921","article-title":"Smartphone voice calls provide early biomarkers of parkinsonism in rapid eye movement sleep behavior disorder","volume":"39","author":"Illner V","year":"2024","journal-title":"Mov Disord"},{"key":"e_1_2_14_99_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2024.105922","article-title":"From prodromal stages to clinical trials: the promise of digital speech biomarkers in Parkinson's disease","volume":"167","author":"Rusz J","year":"2024","journal-title":"Neurosci Biobehav Rev"},{"key":"e_1_2_14_100_1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41531-025-01045-5","article-title":"Digital speech biomarkers can measure acute effects of levodopa in Parkinson's disease","volume":"11","author":"Sousa M","year":"2025","journal-title":"NPJ Park Dis"},{"key":"e_1_2_14_101_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-025-00939-8","article-title":"Detecting neuropsychiatric fluctuations in Parkinson's disease using patients' own words: the potential of large language models","volume":"11","author":"Castelli M","year":"2025","journal-title":"NPJ Park Dis"},{"key":"e_1_2_14_102_1","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1093\/brain\/awx252","article-title":"Beta burst dynamics in Parkinson's disease OFF and ON dopaminergic medication","volume":"140","author":"Tinkhauser G","year":"2017","journal-title":"Brain J Neurol"},{"key":"e_1_2_14_103_1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/mds.10358","article-title":"Oscillatory nature of human basal ganglia activity: relationship to the pathophysiology of Parkinson's disease","volume":"18","author":"Brown P","year":"2003","journal-title":"Mov Disord"},{"key":"e_1_2_14_104_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-023-00567-0","article-title":"Uncovering the neurophysiology of mood, motivation and behavioral symptoms in Parkinson's disease through intracranial recordings","volume":"9","author":"Ricciardi L","year":"2023","journal-title":"NPJ Park Dis"},{"key":"e_1_2_14_105_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-025-01233-3","article-title":"Low\u2010frequency activity in the subthalamic nucleus informs about the acute neuropsychiatric state in Parkinson's disease","volume":"12","author":"Bernasconi E","year":"2026","journal-title":"NPJ Park Dis"},{"key":"e_1_2_14_106_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-024-00848-2","article-title":"Neurophysiological gradient in the parkinsonian subthalamic nucleus as a marker for motor symptoms and apathy","volume":"11","author":"Bernasconi E","year":"2025","journal-title":"NPJ Park Dis"},{"key":"e_1_2_14_107_1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1212\/01.wnl.0000174438.78399.bc","article-title":"Activation of the subthalamic region during emotional processing in Parkinson disease","volume":"65","author":"K\u00fchn AA","year":"2005","journal-title":"Neurology"},{"key":"e_1_2_14_108_1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1460-9568.2007.05683.x","article-title":"The subthalamic region is activated during valence\u2010related emotional processing in patients with Parkinson's disease","volume":"26","author":"Br\u00fccke C","year":"2007","journal-title":"Eur J Neurosci"},{"key":"e_1_2_14_109_1","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/mds.29193","article-title":"Effect of Opicapone on levodopa pharmacokinetics in patients with fluctuating Parkinson's disease","volume":"37","author":"Ferreira JJ","year":"2022","journal-title":"Mov Disord"},{"key":"e_1_2_14_110_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-022-00339-2","article-title":"Effects of MAO\u2010B inhibitors on non\u2010motor symptoms and quality of life in Parkinson's disease: a systematic review","volume":"8","author":"Tsuboi T","year":"2022","journal-title":"NPJ Park Dis"},{"key":"e_1_2_14_111_1","article-title":"Opicapone improves end\u2010of\u2010dose neuropsychiatric fluctuations in patients with Parkinson's disease","volume":"12","author":"Fiores RD","year":"2025","journal-title":"Clin Park Relat Disord"},{"key":"e_1_2_14_112_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/1877718X241306711","article-title":"Opicapone for Parkinson's disease\u2010related sleep disturbances: the OASIS clinical trial","volume":"15","author":"Ferreira JJ","year":"2025","journal-title":"J Parkinsons Dis"},{"key":"e_1_2_14_113_1","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/mdc3.13094","article-title":"Opicapone efficacy and tolerability in Parkinson's Disease patients reporting insufficient benefit\/failure of entacapone","volume":"7","author":"Vokurka P","year":"2020","journal-title":"Mov Disord Clin Pract"},{"key":"e_1_2_14_114_1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41531-025-01090-0","article-title":"Effect of high, low, and asymmetric frequency subthalamic stimulation on speech and voice in Parkinson's disease: a randomized trial","volume":"11","author":"Zeng Z","year":"2025","journal-title":"NPJ Park Dis"},{"key":"e_1_2_14_115_1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mdc3.12921","article-title":"Levodopa equivalent dose conversion factors: an updated proposal including Opicapone and safinamide","volume":"7","author":"Schade S","year":"2020","journal-title":"Mov Disord Clin Pract"},{"key":"e_1_2_14_116_1","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.3390\/jcm14082598","article-title":"The role of MAO\u2010B inhibitors in fatigue in Parkinson's disease: a narrative review","volume":"14","author":"Galli S","year":"2025","journal-title":"J Clin Med"},{"key":"e_1_2_14_117_1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamaneurol.2021.4736","article-title":"Long\u2010term effectiveness of adjuvant treatment with catechol\u2010O\u2010methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists among patients with Parkinson disease uncontrolled by levodopa therapy: the PD MED randomized clinical trial","volume":"79","author":"Gray R","year":"2022","journal-title":"JAMA Neurol"},{"key":"e_1_2_14_118_1","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.2174\/1570159X20666220905102144","article-title":"Monoamine\u2010oxidase type B inhibitors and cognitive functions in Parkinson'sDisease: beyond the primary mechanism of action","volume":"21","author":"Rinaldi D","year":"2023","journal-title":"Curr Neuropharmacol"},{"key":"e_1_2_14_119_1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jocn.2021.05.056","article-title":"The role of glutamatergic neurotransmission in the motor and non\u2010motor symptoms in Parkinson's disease: clinical cases and a review of the literature","volume":"90","author":"Pagonabarraga J","year":"2021","journal-title":"J Clin Neurosci"},{"key":"e_1_2_14_120_1","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00702-022-02538-w","article-title":"Non\u2010motor symptoms burden in motor\u2010fluctuating patients with Parkinson's disease may be alleviated by safinamide: the VALE\u2010SAFI study","volume":"129","author":"Masi C","year":"2022","journal-title":"J Neural Transm"},{"key":"e_1_2_14_121_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713334","article-title":"Striking neurochemical and behavioral differences in the mode of action of selegiline and Rasagiline","volume":"24","author":"Harsing LG","year":"2023","journal-title":"Int J Mol Sci"},{"key":"e_1_2_14_122_1","doi-asserted-by":"crossref","DOI":"10.1001\/archneur.58.9.1385","article-title":"A randomized, double\u2010blind, placebo\u2010controlled trial of subcutaneously injected apomorphine for parkinsonian off\u2010state events","volume":"58","author":"Dewey RB","year":"2001","journal-title":"Arch Neurol"},{"key":"e_1_2_14_123_1","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1007\/s00415-024-12323-2","article-title":"Long\u2010term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open\u2010label study","volume":"271","author":"Kassubek J","year":"2024","journal-title":"J Neurol"},{"key":"e_1_2_14_124_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1474-4422(18)30405-8","article-title":"Safety and efficacy of CVT\u2010301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double\u2010blind, placebo\u2010controlled phase 3 trial","volume":"18","author":"LeWitt PA","year":"2019","journal-title":"Lancet Neurol"},{"key":"e_1_2_14_125_1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1474-4422(03)00529-5","article-title":"Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?","volume":"2","author":"Lawrence AD","year":"2003","journal-title":"Lancet Neurol"},{"key":"e_1_2_14_126_1","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.parkreldis.2013.02.018","article-title":"Rotigotine and specific non\u2010motor symptoms of Parkinson's disease: Post hoc analysis of RECOVER","volume":"19","author":"Ray Chaudhuri K","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"e_1_2_14_127_1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","article-title":"Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double\u2010blind, placebo\u2010controlled trial","volume":"9","author":"Barone P","year":"2010","journal-title":"Lancet Neurol"},{"key":"e_1_2_14_128_1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1212\/WNL.0000000000000050","article-title":"Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial","volume":"82","author":"Ory\u2010Magne F","year":"2014","journal-title":"Neurology"},{"key":"e_1_2_14_129_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-022-00291-1","article-title":"Amantadine delayed release\/extended release capsules significantly reduce OFF time in Parkinson's disease","volume":"8","author":"Hauser RA","year":"2022","journal-title":"NPJ Park Dis"},{"key":"e_1_2_14_130_1","first-page":"e189","article-title":"Longitudinal analysis of impulse control disorders in Parkinson disease","volume":"91","author":"Corvol J\u2010C","year":"2018","journal-title":"Neurology"},{"key":"e_1_2_14_131_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.294"},{"key":"e_1_2_14_132_1","doi-asserted-by":"crossref","DOI":"10.3390\/cells11091511","article-title":"Effects of one\u2010day application of levodopa\/carbidopa\/entacapone versus levodopa\/carbidopa\/Opicapone in Parkinson's disease patients","volume":"11","author":"M\u00fcller T","year":"2022","journal-title":"Cells"},{"key":"e_1_2_14_133_1","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ana.22029","article-title":"Pathological gambling in Parkinson disease is reduced by amantadine","volume":"68","author":"Thomas A","year":"2010","journal-title":"Ann Neurol"},{"key":"e_1_2_14_134_1","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ana.22164","article-title":"Amantadine use associated with impulse control disorders in Parkinson disease in cross\u2010sectional study","volume":"68","author":"Weintraub D","year":"2010","journal-title":"Ann Neurol"},{"key":"e_1_2_14_135_1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.neurol.2024.06.008","article-title":"Influence of continuous subcutaneous apomorphine infusion on cognition and behavior in Parkinson's disease: a systematic review","volume":"181","author":"Houvenaghel J\u2010F","year":"2025","journal-title":"Rev Neurol (Paris)"},{"key":"e_1_2_14_136_1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1474-4422(24)00052-8","article-title":"Safety and efficacy of continuous subcutaneous levodopa\u2013carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double\u2010blind, double\u2010dummy, multicentre trial","volume":"23","author":"Espay AJ","year":"2024","journal-title":"Lancet Neurol"},{"key":"e_1_2_14_137_1","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","article-title":"Safety and efficacy of continuous subcutaneous foslevodopa\u2010foscarbidopa in patients with advanced Parkinson's disease: a randomised, double\u2010blind, active\u2010controlled, phase 3 trial","volume":"21","author":"Soileau MJ","year":"2022","journal-title":"Lancet Neurol"},{"key":"e_1_2_14_138_1","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/mds.22596","article-title":"Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life","volume":"24","author":"Honig H","year":"2009","journal-title":"Mov Disord"},{"key":"e_1_2_14_139_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","article-title":"Continuous intrajejunal infusion of levodopa\u2010carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double\u2010blind, double\u2010dummy study","volume":"13","author":"Olanow CW","year":"2014","journal-title":"Lancet Neurol"},{"key":"e_1_2_14_140_1","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16535","article-title":"Effectiveness and safety of levodopa\u2013entacapone\u2013carbidopa infusion in Parkinson disease: a real\u2010world data study","volume":"32","author":"Santos\u2010Garc\u00eda D","year":"2025","journal-title":"Eur J Neurol"},{"key":"e_1_2_14_141_1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/mds.26855","article-title":"Levodopa\u2010entacapone\u2010carbidopa intestinal gel in Parkinson's disease: A randomized crossover study: Levodopa\u2010Entacapone\u2010Carbidopa Intestinal Gel","volume":"32","author":"Senek M","year":"2017","journal-title":"Mov Disord"},{"key":"e_1_2_14_142_1","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1056\/NEJMoa2016311","article-title":"Randomized trial of focused ultrasound subthalamotomy for Parkinson's disease","volume":"383","author":"Mart\u00ednez\u2010Fern\u00e1ndez R","year":"2020","journal-title":"N Engl J Med"},{"key":"e_1_2_14_143_1","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/jamaneurol.2017.3098","article-title":"Safety and efficacy of focused ultrasound thalamotomy for patients with medication\u2010refractory, tremor\u2010dominant Parkinson disease: a randomized clinical trial","volume":"74","author":"Bond AE","year":"2017","journal-title":"JAMA Neurol"},{"key":"e_1_2_14_144_1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2202721","article-title":"Trial of globus pallidus focused ultrasound ablation in Parkinson's disease","volume":"388","author":"Krishna V","year":"2023","journal-title":"N Engl J Med"},{"key":"e_1_2_14_145_1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jns.2016.11.080","article-title":"Apomorphine pump in advanced Parkinson's disease: effects on motor and nonmotor symptoms with brain metabolism correlations","volume":"372","author":"Auffret M","year":"2017","journal-title":"J Neurol Sci"},{"key":"e_1_2_14_146_1","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00415-016-8106-3","article-title":"Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study","volume":"263","author":"Drapier S","year":"2016","journal-title":"J Neurol"},{"key":"e_1_2_14_147_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-021-00194-7","article-title":"Long\u2010term effect of apomorphine infusion in advanced Parkinson's disease: a real\u2010life study","volume":"7","author":"Meira B","year":"2021","journal-title":"NPJ Park Dis"},{"key":"e_1_2_14_148_1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.neuron.2010.11.022","article-title":"Dopamine in motivational control: rewarding, aversive, and alerting","volume":"68","author":"Bromberg\u2010Martin ES","year":"2010","journal-title":"Neuron"},{"key":"e_1_2_14_149_1","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/brain\/aws078","article-title":"Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours","volume":"135","author":"Lhomm\u00e9e E","year":"2012","journal-title":"Brain"},{"key":"e_1_2_14_150_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-024-00811-1","article-title":"Deciphering the effects of STN DBS on neuropsychiatric fluctuations in Parkinson's disease","volume":"10","author":"Muldmaa M","year":"2024","journal-title":"NPJ Park Dis"},{"key":"e_1_2_14_151_1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1136\/jnnp-2012-302387","article-title":"Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease","volume":"84","author":"Eusebio A","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_14_152_1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jnnp-2012-303988","article-title":"Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long\u2010term outcome","volume":"85","author":"Cilia R","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_14_153_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029768","article-title":"Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome","volume":"7","author":"Moum SJ","year":"2012","journal-title":"PLoS One"},{"key":"e_1_2_14_154_1","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jocn.2008.12.010","article-title":"Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease","volume":"16","author":"Lim S\u2010Y","year":"2009","journal-title":"J Clin Neurosci"},{"key":"e_1_2_14_155_1","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1056\/NEJMoa0907083","article-title":"Pallidal versus subthalamic deep\u2010brain stimulation for Parkinson's disease","volume":"362","author":"Follett KA","year":"2010","journal-title":"N Engl J Med"},{"key":"e_1_2_14_156_1","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.3171\/2016.11.JNS16715","article-title":"Deep brain stimulation for Parkinson's disease: meta\u2010analysis of results of randomized trials at varying lengths of follow\u2010up","volume":"128","author":"Mansouri A","year":"2018","journal-title":"J Neurosurg"},{"key":"e_1_2_14_157_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-021-00223-5","article-title":"Subthalamic and pallidal deep brain stimulation for Parkinson's disease\u2014meta\u2010analysis of outcomes","volume":"7","author":"Lachenmayer ML","year":"2021","journal-title":"NPJ Park Dis"},{"key":"e_1_2_14_158_1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/neuros\/nyy037","article-title":"Congress of Neurological Surgeons systematic review and evidence\u2010based guideline on subthalamic nucleus and globus pallidus internus deep brain stimulation for the treatment of patients with Parkinson's disease: executive summary","volume":"82","author":"Rughani A","year":"2018","journal-title":"Neurosurgery"},{"key":"e_1_2_14_159_1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jamaneurol.2017.4321","article-title":"Globus pallidus interna or subthalamic nucleus deep brain stimulation for Parkinson disease: a review","volume":"75","author":"Ramirez\u2010Zamora A","year":"2018","journal-title":"JAMA Neurol"},{"key":"e_1_2_14_160_1","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/mdc3.70042","article-title":"Clinical and imaging correlates of medication reduction in globus pallidus stimulation for Parkinson's disease","volume":"12","author":"Luca DG","year":"2025","journal-title":"Mov Disord Clin Pract"},{"key":"e_1_2_14_161_1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/mdc3.12004","article-title":"Subthalamic nucleus versus globus pallidus internus deep brain stimulation: translating the rematch into clinical practice","volume":"1","author":"Williams NR","year":"2014","journal-title":"Mov Disord Clin Pract"},{"key":"e_1_2_14_162_1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1474-4422(18)30035-8","article-title":"Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open\u2010label randomised trial","volume":"17","author":"Lhomm\u00e9e E","year":"2018","journal-title":"Lancet Neurol"},{"key":"e_1_2_14_163_1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease\u2014an evidence\u2010based medicine review","volume":"34","author":"Seppi K","year":"2019","journal-title":"Mov Disord"},{"key":"e_1_2_14_164_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041470"},{"key":"e_1_2_14_165_1","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/mds.25098","article-title":"Donepezil in Parkinson's disease dementia: a randomized, double\u2010blind efficacy and safety study","volume":"27","author":"Dubois B","year":"2012","journal-title":"Mov Disord"},{"key":"e_1_2_14_166_1","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/mds.21077","article-title":"Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease","volume":"21","author":"Burn D","year":"2006","journal-title":"Mov Disord"},{"key":"e_1_2_14_167_1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up","volume":"75","author":"Pollak P","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_14_168_1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo\u2010controlled phase 3 trial","volume":"383","author":"Cummings J","year":"2014","journal-title":"Lancet"},{"key":"e_1_2_14_169_1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/mdc3.12167","article-title":"Clozapine treatment for impulse control disorders in Parkinson's disease patients: a Case series","volume":"2","author":"Liang J","year":"2015","journal-title":"Mov Disord Clin Pract"},{"key":"e_1_2_14_170_1","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/mds.23177","article-title":"Clozapine for medication\u2010related pathological gambling in Parkinson disease","volume":"25","author":"Rotondo A","year":"2010","journal-title":"Mov Disord"},{"key":"e_1_2_14_171_1","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1007\/s00213-015-4048-1","article-title":"Clozapine use for refractory impulse control disorders in Parkinson's disease: a case report","volume":"232","author":"Bonfils NA","year":"2015","journal-title":"Psychopharmacology"},{"key":"e_1_2_14_172_1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/13554794.2012.713490","article-title":"Clozapine as a potential treatment for refractory impulsive, compulsive, and punding behaviors in Parkinson's disease","volume":"19","author":"Hardwick A","year":"2013","journal-title":"Neurocase"},{"key":"e_1_2_14_173_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-020-00142-x","article-title":"A randomized controlled double\u2010blind study of rotigotine on neuropsychiatric symptoms in de novo PD","volume":"6","author":"Castrioto A","year":"2020","journal-title":"NPJ Park Dis"},{"key":"e_1_2_14_174_1","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1176\/appi.ajp.2011.10111669","article-title":"Cognitive\u2010behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial","volume":"168","author":"Dobkin RD","year":"2011","journal-title":"Am J Psychiatry"},{"key":"e_1_2_14_175_1","doi-asserted-by":"crossref","first-page":"e1764","DOI":"10.1212\/WNL.0000000000009292","article-title":"Telephone\u2010based cognitive behavioral therapy for depression in Parkinson disease: a randomized controlled trial","volume":"94","author":"Dobkin RD","year":"2020","journal-title":"Neurology"},{"key":"e_1_2_14_176_1","doi-asserted-by":"crossref","DOI":"10.1186\/1471-244X-14-19","article-title":"A waitlist\u2010controlled trial of group cognitive behavioural therapy for depression and anxiety in Parkinson's disease","volume":"14","author":"Troeung L","year":"2014","journal-title":"BMC Psychiatry"},{"key":"e_1_2_14_177_1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3233\/JPD-230035","article-title":"Anxiety in Parkinson's disease is associated with changes in brain structural connectivity","volume":"13","author":"Carey G","year":"2023","journal-title":"J Parkinsons Dis"},{"key":"e_1_2_14_178_1","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1002\/mds.28533","article-title":"Cognitive behavioral therapy for anxiety in Parkinson's disease: a randomized controlled trial","volume":"36","author":"Moonen AJH","year":"2021","journal-title":"Mov Disord"},{"key":"e_1_2_14_179_1","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1212\/WNL.0b013e3182840678","article-title":"Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers","volume":"80","author":"Okai D","year":"2013","journal-title":"Neurology"},{"key":"e_1_2_14_180_1","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamaneurol.2019.0534","article-title":"Effects of mindfulness yoga vs stretching and resistance training exercises on anxiety and depression for people with Parkinson disease: a randomized clinical trial","volume":"76","author":"Kwok JYY","year":"2019","journal-title":"JAMA Neurol"},{"key":"e_1_2_14_181_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-023-00452-w","article-title":"A randomized clinical trial of mindfulness meditation versus exercise in Parkinson's disease during social unrest","volume":"9","author":"Kwok JYY","year":"2023","journal-title":"NPJ Park Dis"}],"container-title":["Movement Disorders Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70771","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mdc3.70771","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:58:35Z","timestamp":1789541915000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mdc3.70771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":180,"alternative-id":["10.1002\/mdc3.70771"],"URL":"https:\/\/doi.org\/10.1002\/mdc3.70771","archive":["Portico"],"relation":{},"ISSN":["2330-1619","2330-1619"],"issn-type":[{"value":"2330-1619","type":"print"},{"value":"2330-1619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"2026-03-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"mdc3.70771"}}